Literature DB >> 25555887

Predictors of long term opioid withdrawal outcome after short-term stabilization with buprenorphine.

M I Saleh1.   

Abstract

OBJECTIVE: We aim to examine predictors of opiate abstinence status 3 months after the end of buprenorphine/naloxone treatment for opioid-dependent participants. PATIENTS AND METHODS: Participants (n= 516, age > 15 years) received buprenorphine/ naloxone treatment for 4 weeks and then randomly assigned to undergo dose tapering over either 7 days or 28 days. Bivariate analysis was performed to identify possible predictors of successful opiate abstinence outome (p-value < 0.10). Logistic regression analysis with backward stepwise selection was, then, performed to produce final model containing independent predictors at p-value < 0.05.
RESULTS: Bivariate analysis identified several possible predictors including: opioid and drug urine tests result at the end taper; employment status, family problems, and alcohol use domains of addiction severity index (ASI) score; and clinical opiate withdrawal scale (COWS) at the end of stabilization. Final predictor list identified by logistic regression include: ASI score for family and alcohol problems, COWS at the end of stabilization and opiate urine test at the end of taper.
CONCLUSIONS: Participants presenting with a negative urine test for opiate, more severe alcohol, more severe family problems, or more symptoms of opiate withdrawal at the end of stabilization were more likely to have a successful opiate abstinence.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25555887

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

1.  A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.

Authors:  Mohammad I Saleh; Nagham N Hindi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-05       Impact factor: 3.000

Review 2.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.